Discover undervalued stocks with Eulerpool.

Subscribe for $2

MacroGenics Stock MGNX

Price

0
Today +/-
-0
Today %
-0 %

MacroGenics stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the MacroGenics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the MacroGenics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the MacroGenics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze MacroGenics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

MacroGenics Stock Price History

DateMacroGenics Price
10/7/20250 undefined
10/7/20251.74 undefined
10/6/20251.77 undefined
10/3/20251.80 undefined
10/2/20251.68 undefined
10/1/20251.72 undefined
9/30/20251.73 undefined
9/28/20251.75 undefined
9/25/20251.73 undefined
9/24/20251.65 undefined
9/24/20251.74 undefined
9/24/20251.75 undefined
9/23/20251.71 undefined
9/22/20251.75 undefined
9/19/20251.68 undefined
9/19/20251.64 undefined
9/18/20251.75 undefined
9/17/20251.58 undefined
9/16/20251.52 undefined
9/15/20251.58 undefined
9/12/20251.60 undefined
9/12/20251.60 undefined
9/11/20251.70 undefined
9/10/20251.73 undefined
9/9/20251.75 undefined
9/8/20251.77 undefined

MacroGenics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into MacroGenics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by MacroGenics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects MacroGenics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of MacroGenics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into MacroGenics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing MacroGenics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on MacroGenics’s growth potential.

MacroGenics Revenue, EBIT and net profit per share

DateMacroGenics RevenueMacroGenics EBITMacroGenics Net Income
2030e257.89 M undefined0 undefined0 undefined
2029e146.99 M undefined-208.25 M undefined13.41 M undefined
2028e104.73 M undefined-225.49 M undefined-95.81 M undefined
2027e34.55 M undefined-211.68 M undefined-128.17 M undefined
2026e45.42 M undefined-159.56 M undefined-103.83 M undefined
2025e71.43 M undefined-164.87 M undefined-127.36 M undefined
2024149.96 M undefined-110.58 M undefined-66.97 M undefined
202358.75 M undefined-168.24 M undefined-9.06 M undefined
2022151.9 M undefined-121.4 M undefined-119.8 M undefined
202177.4 M undefined-202.8 M undefined-202.1 M undefined
2020104.9 M undefined-131.1 M undefined-129.7 M undefined
201964.2 M undefined-177.2 M undefined-151.8 M undefined
201860.1 M undefined-171.2 M undefined-171.5 M undefined
2017157.7 M undefined-22.1 M undefined-19.6 M undefined
201691.9 M undefined-60 M undefined-58.5 M undefined
2015100.9 M undefined-20.2 M undefined-20.1 M undefined
201447.8 M undefined-38.3 M undefined-38.3 M undefined
201358 M undefined400,000 undefined-300,000 undefined
201263.8 M undefined8.2 M undefined8.4 M undefined
201157.2 M undefined5.2 M undefined6.7 M undefined

MacroGenics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
576358471009115760641047715158149714534104146257
-10.53-7.94-18.97112.77-9.0072.53-61.786.6762.50-25.9696.10-61.59156.90-52.35-36.62-24.44205.8840.3876.03
240.35217.46236.21291.49137.00150.5587.26228.33214.06131.7396.1095.3686.2191.95192.96304.44402.94131.7393.8453.31
00000000007414450137000000
680-38-20-58-19-171-151-129-202-119-9-66-127-103-128-95130
-33.33---47.37190.00-67.24800.00-11.70-14.5756.59-41.09-92.44633.3392.42-18.9024.27-25.78-113.68-
2421.52427.431.834.736.140.948.152.459.961.461.9362.62000000
- - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The MacroGenics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the MacroGenics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (M)
OTHER EQUITY (k)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
20112012201320142015201620172018201920202021202220232024
                           
55.247.7116.5157.6339277305.1232.9215.8272.5243.6154.3229.81201.67
3.4222.91.22.813.629.612.723.110.456.210.374.31
00000000000000
00000000004.41.51.220
00.114.22.14.23.66.711.31721.210.29.9511.51
58.649.8119.5164.7342.3284322.3269.2239.8312.6279.6222.2251.34217.49
3.33.356.814.8185056.748.261.454.356.945.6942.61
00000800000000
00000000000000
00000000000000
00000000000000
0.70.61.32.421.41.66.324.54.71.41.41.391.56
43.96.39.216.827.451.66372.766.155.758.347.0844.17
62.653.7125.8173.9359.1311.4373.9332.2312.5378.7335.3280.5298.42261.66
                           
2.92.90.30.30.30.30.40.40.50.60.60.60.620.63
0.160.160.250.340.550.560.610.730.871.071.211.241.251.29
-183.8-175.5-175.7-214-234.2-292.7-312.3-490.3-642.1-771.8-973.9-1,093.7-1,102.75-1,169.72
00000-100-100000-1000-64
00000000000000
-17.5-8.379.1121.4313.3268.7299.3242.8230.6296239.6142152.61116.06
11.13.73.21.7342.544.3815.54.96.445.01
1.11.23.67.911.716.138.63330.238.238.433.728.0134.2
31.724.120.615.97.55.68.422.910.74.520.61021.6516.32
00000000000000
0.50.61.41.621.60.30000000
44.429.628.827.124.227.349.859.945.250.774.548.656.1155.53
10.19.406.42.70.300000000
00000000000000
25.822.81819.11914.924.929.336.732.22189.889.790.07
35.932.21825.521.715.224.929.336.732.22189.889.790.07
80.361.846.852.645.942.574.789.281.982.995.5138.4145.81145.6
62.853.5125.9174359.2311.2374332312.5378.9335.1280.4298.42261.65
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of MacroGenics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand MacroGenics's financial health and stability.

Assets

MacroGenics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that MacroGenics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of MacroGenics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into MacroGenics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
680-38-20-58-19-171-151-129-202-119-9
10112778101111119
0000000000000
-2-16-160-4-412-6-12-1420-2-245
31261524293339414944184
0000000000000
0000000000000
6-6-14-32-13-4314-153-134-111-143-86-78
00-2-3-9-11-29-24-4-5-6-3-1
00-2-3-152-707756-79-7-3670-80
0000-142-5810781-75-1-3074-78
0000000000000
0000000000000
120857720413510411917412210
12085772041351041191741221150
000000000000149
0000000000000
18-7684138-1121278-9354-57-14-7
6.26-7.52-17.13-36.33-22.86-55.06-14.99-178.18-138.56-117.81-150.03-90.58-79.97
0000000000000

MacroGenics stock margins

The MacroGenics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MacroGenics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MacroGenics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the MacroGenics's sales revenue. A higher gross margin percentage indicates that the MacroGenics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the MacroGenics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the MacroGenics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the MacroGenics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the MacroGenics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the MacroGenics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

MacroGenics Margin History

MacroGenics Gross marginMacroGenics Profit marginMacroGenics EBIT marginMacroGenics Profit margin
2030e91.8 %0 %0 %
2029e91.8 %-141.68 %9.13 %
2028e91.8 %-215.31 %-91.48 %
2027e91.8 %-612.62 %-370.95 %
2026e91.8 %-351.33 %-228.63 %
2025e91.8 %-230.82 %-178.32 %
202491.8 %-73.74 %-44.66 %
202386 %-286.38 %-15.42 %
202295.19 %-79.92 %-78.87 %
202196.64 %-262.02 %-261.11 %
202091.8 %-124.98 %-123.64 %
201991.8 %-276.01 %-236.45 %
201891.8 %-284.86 %-285.36 %
201791.8 %-14.01 %-12.43 %
201691.8 %-65.29 %-63.66 %
201591.8 %-20.02 %-19.92 %
201491.8 %-80.13 %-80.13 %
201391.8 %0.69 %-0.52 %
201291.8 %12.85 %13.17 %
201191.8 %9.09 %11.71 %

MacroGenics Stock Sales Revenue, EBIT, Earnings per Share

The MacroGenics earnings per share therefore indicates how much revenue MacroGenics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue MacroGenics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates MacroGenics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of MacroGenics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating MacroGenics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

MacroGenics Revenue, EBIT and net profit per share

DateMacroGenics Sales per ShareMacroGenics EBIT per shareMacroGenics Earnings per Share
2030e4.12 undefined0 undefined0 undefined
2029e2.35 undefined0 undefined0.21 undefined
2028e1.67 undefined0 undefined-1.53 undefined
2027e0.55 undefined0 undefined-2.05 undefined
2026e0.73 undefined0 undefined-1.66 undefined
2025e1.14 undefined0 undefined-2.03 undefined
20242.39 undefined-1.77 undefined-1.07 undefined
20230.95 undefined-2.72 undefined-0.15 undefined
20222.47 undefined-1.98 undefined-1.95 undefined
20211.29 undefined-3.39 undefined-3.37 undefined
20202 undefined-2.5 undefined-2.48 undefined
20191.33 undefined-3.68 undefined-3.16 undefined
20181.47 undefined-4.19 undefined-4.19 undefined
20174.37 undefined-0.61 undefined-0.54 undefined
20162.65 undefined-1.73 undefined-1.69 undefined
20153.17 undefined-0.64 undefined-0.63 undefined
20141.74 undefined-1.4 undefined-1.4 undefined
20132.42 undefined0.02 undefined-0.01 undefined
20122.97 undefined0.38 undefined0.39 undefined
20112.38 undefined0.22 undefined0.28 undefined

MacroGenics business model

MacroGenics Inc is a biotechnology company that was founded in 2000 and is headquartered in Rockville, Maryland, USA. The company specializes in the research, development, and commercialization of therapeutic antibodies used in the treatment of cancer and autoimmune diseases. MacroGenics' business model is based on the production of different antibodies that primarily target various cell types and thereby elicit a targeted response. The company relies on a balanced approach to research and development to preferentially identify cellular markers that are characteristic of certain diseases, allowing for the identification of specific target molecules for antibody development. These innovative therapies lead to an improvement in the quality of life for patients by curing or at least managing severe diseases. Over the years, MacroGenics has built several divisions, including: Antibody platform technologies MacroGenics utilizes its proprietary platform technology for phage display and antibody manufacturing (Digitalis), as well as for the discovery of target molecules responsible for specific diseases. These technologies are used to identify new therapeutic antibody candidates and support the entire antibody development process. Cancer research and development MacroGenics is a pioneer in the development of innovative cancer therapies. One of the key products in this area is the antibody-based cancer drug Margetuximab, used for the treatment of metastatic breast cancer. Another promising drug in clinical phases is MGD019, which is highly effective for tumor treatment in the solid area. Autoimmune research and development MacroGenics is a leading developer of Neuromyelitis Optica Spectrum Disorder (NMOSD), which leads to recurring inflammation of the central nervous system. Additional products in the pipeline are being developed for the treatment of autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, as there is still a wide range of needs in this field. Polyclonals and biosimilars This area includes the production of antibody polypeptides and biosimilar drugs. Antibody polypeptides can be used to treat infectious diseases or diagnose diseases. Biosimilar drugs are biological drugs that have similar active ingredients to other already approved drugs and are approved by the US Food and Drug Administration (FDA). These drugs are also known as generic replicas. MacroGenics' products have proven to be safe and effective in clinical trials. The company has established an extensive network of collaborations to market and distribute its products. Partners include major pharmaceutical companies such as Pfizer, Servier, and Janssen Biotech. Overall, MacroGenics has over 20 product pipelines in various stages of development and is constantly working to expand its product pipelines. The company employs over 400 employees and aims to revolutionize the treatment of severe and life-threatening diseases. In conclusion, MacroGenics Inc is an innovative biotechnology company that has developed and designed a variety of products for the treatment of cancer and autoimmune diseases. The company has a wide range of proprietary platform technologies and is constantly striving to expand its product pipelines. We expect the company to continue growing in the coming years and harness its innovative power to further benefit patients. MacroGenics is one of the most popular companies on Eulerpool.com.

MacroGenics SWOT Analysis

Strengths

1. Strong research and development capabilities in the field of biotechnology.

2. Well-established strategic partnerships with leading pharmaceutical companies.

3. Robust intellectual property portfolio with numerous patents.

4. Skilled and experienced management team with expertise in the biotech industry.

Weaknesses

1. Heavy reliance on a limited number of drug candidates in the pipeline.

2. Vulnerability to regulatory challenges and delays in drug approvals.

3. High operating costs associated with the development and clinical trials of new drugs.

4. Limited market presence compared to larger pharmaceutical competitors.

Opportunities

1. Growing demand for novel biologic therapies in the healthcare market.

2. Potential expansion into international markets to increase revenue streams.

3. Collaborations with academic institutions for research advancements and talent acquisition.

4. Increasing investments in precision medicine and personalized healthcare.

Threats

1. Intense competition from other biotech and pharmaceutical companies.

2. Rising costs of research and development, potentially impacting profitability.

3. Regulatory changes and stricter compliance requirements for drug development and commercialization.

4. Uncertainties associated with the outcome of clinical trials and drug efficacy.

MacroGenics Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

MacroGenics Revenue by Segment

Segmente202320222021202020192018
Revenue from collaborative agreements28.99 M USD119.3 M USD63.29 M USD97.76 M USD62.02 M USD540,000 USD
Product17.94 M USD16.73 M USD12.35 M USD---
Contract Manufacturing9.83 M USD13.99 M USD----
Revenue from government agreements1.56 M USD1.92 M USD1.8 M USD7.12 M USD2.16 M USD1.48 M USD
RevenueFromRoyalityAgreementsMember431,000 USD-----
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

MacroGenics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

MacroGenics historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

MacroGenics shares outstanding

The number of shares was MacroGenics in 2024 — This indicates how many shares 62.621 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue MacroGenics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates MacroGenics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of MacroGenics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating MacroGenics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for MacroGenics.

MacroGenics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2025-0.62 -0.57  (8.09 %)2025 Q2
3/31/2025-0.8 -0.65  (18.5 %)2025 Q1
12/31/2024-0.44 -0.25  (43.81 %)2024 Q4
9/30/20240.22 0.9  (316.28 %)2024 Q3
6/30/2024-0.6 -0.89  (-48.21 %)2024 Q2
3/31/2024-0.66 -0.84  (-28.11 %)2024 Q1
12/31/2023-0.16 -0.75  (-378.32 %)2023 Q4
9/30/2023-0.1 0.28  (387.18 %)2023 Q3
6/30/2023-0.53 -0.69  (-29.8 %)2023 Q2
3/31/20230.46 -0.61  (-232.26 %)2023 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the MacroGenics stock

Eulerpool World ESG Rating (EESG©)

78/ 100

🌱 Environment

73

👫 Social

87

🏛️ Governance

75

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees59
Percentage of women in management
Percentage of Asian employees26
Share of Asian management13
Percentage of Hispanic/Latino employees9
Hispano/Latino Management share
Percentage of Black employees16
Black Management Share
Percentage of white employees46
White Management Share80
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

MacroGenics shareholders

%
Name
Stocks
Change
Date
15.84127 % Bellevue Asset Management AG9,919,992-9,9716/30/2025
9.51754 % Armistice Capital LLC5,960,000-336,0006/30/2025
6.72794 % The Vanguard Group, Inc.4,213,114-212,8786/30/2025
5.19157 % Wasatch Global Investors Inc3,251,0227746/30/2025
5.07123 % Frazier Life Sciences Management, L.P.3,175,66506/30/2025
3.97901 % Acadian Asset Management LLC2,491,703183,0546/30/2025
3.21914 % Millennium Management LLC2,015,864291,6146/30/2025
2.78346 % BlackRock Institutional Trust Company, N.A.1,743,033-2,755,0096/30/2025
2.55938 % EcoR1 Capital, LLC1,602,7171,602,7176/30/2025
2.27640 % Koenig (Scott)1,425,50652,8298/13/2025
1
2
3
4
5
...
10

MacroGenics Executives and Management Board

Dr. Ezio Bonvini

(70)
MacroGenics Senior Vice President - Research, Chief Scientific Officer
Compensation 2.29 M

Mr. Eric Risser

(51)
MacroGenics Chief Operating Officer
Compensation 1.92 M

Mr. Thomas Spitznagel

(57)
MacroGenics Senior Vice President - Technical Operations
Compensation 1.88 M

Dr. Stephen Eck

(69)
MacroGenics Senior Vice President - Clinical Development, Chief Medical Officer
Compensation 1.75 M

Mr. James Karrels

(57)
MacroGenics Chief Financial Officer, Senior Vice President, Corporate Secretary
Compensation 1.58 M
1
2
3
4

MacroGenics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
ImmunoGen Stock
ImmunoGen
SupplierCustomer0,930,900,810,930,550,28
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer0,76-0,14-0,60-0,73-0,43-0,50
Alligator Bioscience Stock
Alligator Bioscience
SupplierCustomer0,690,130,800,760,800,72
Provention Bio Stock
Provention Bio
SupplierCustomer0,690,830,890,190,450,45
AGC Stock
AGC
SupplierCustomer0,530,05-0,050,770,14-0,39
I-MAB ADR Stock
I-MAB ADR
SupplierCustomer0,480,770,710,940,970,57
Bellevue Group Stock
Bellevue Group
SupplierCustomer0,310,940,790,580,58-0,27
Baxter Intl Stock
Baxter Intl
SupplierCustomer0,23-0,700,610,720,120,35
Incyte Stock
Incyte
SupplierCustomer0,190,450,30-0,390,060,49
BlackRock Stock
BlackRock
SupplierCustomer0,040,720,890,980,84
1
2

Most common questions regarding MacroGenics

What values and corporate philosophy does MacroGenics represent?

The values and corporate philosophy that MacroGenics Inc represents are centered around their commitment to discovering and developing innovative biopharmaceutical products. The company strives to deliver impactful medicines to improve the lives of patients. MacroGenics Inc focuses on excellence, integrity, and collaboration in their research and development efforts. They aim to be a trusted partner and create value for their stakeholders through their cutting-edge science and dedication to advancing healthcare. With a focus on science-driven discovery and a patient-centric approach, MacroGenics Inc aims to bring transformative therapies to market.

In which countries and regions is MacroGenics primarily present?

MacroGenics Inc is primarily present in the United States.

What significant milestones has the company MacroGenics achieved?

MacroGenics Inc, a renowned biopharmaceutical company, has achieved several significant milestones in its impressive journey. Notably, the company successfully developed and received regulatory approvals for multiple clinical-stage product candidates, showcasing its commitment to advancing innovative therapies. MacroGenics Inc's most notable achievement includes the FDA approval of margetuximab, a treatment for patients with HER2-positive metastatic breast cancer. Moreover, the company has established strategic collaborations with leading pharmaceutical companies, further validating its research and development capabilities. With its strong focus on precision medicine and novel antibody-based therapeutics, MacroGenics Inc continues to drive breakthrough advancements in the field of biotechnology.

What is the history and background of the company MacroGenics?

MacroGenics Inc is a biopharmaceutical company based in Rockville, Maryland. Established in 2000, MacroGenics has been dedicated to developing innovative antibody-based therapies for patients with cancer and autoimmune disorders. With a strong focus on research and development, the company has built a robust pipeline of product candidates targeting different diseases. MacroGenics has achieved several milestones, including FDA approvals and collaborations with notable pharmaceutical companies. With its experienced team and cutting-edge technology, MacroGenics continues to strive towards improving patients' lives through the development of novel therapies.

Who are the main competitors of MacroGenics in the market?

The main competitors of MacroGenics Inc in the market include larger pharmaceutical companies such as Bristol-Myers Squibb, Pfizer, and Novartis. These companies also operate in the biopharmaceutical industry and have a similar focus on developing innovative therapies and treatments. MacroGenics Inc faces competition from these established players in terms of product development, market share, and financial performance. However, MacroGenics Inc has its own unique portfolio of proprietary drug candidates and strategic collaborations which help it remain competitive in the market.

In which industries is MacroGenics primarily active?

MacroGenics Inc is primarily active in the biotechnology industry.

What is the business model of MacroGenics?

The business model of MacroGenics Inc is focused on developing innovative antibody-based therapeutics for the treatment of cancer. The company utilizes its proprietary technology platforms to discover, design, and optimize monoclonal and multi-specific antibodies. By leveraging its expertise in antibody engineering and targeting mechanisms, MacroGenics aims to create novel therapies that have the potential to improve patient outcomes. With a strong pipeline of product candidates targeting various cancer indications, MacroGenics Inc strives to advance medical innovation and bring transformative treatments to patients in need.

What is the P/E ratio of MacroGenics 2025?

The P/E ratio cannot be calculated for MacroGenics at the moment.

What is the P/S ratio of MacroGenics 2025?

The P/S cannot be calculated for MacroGenics currently.

What is the Quality Investing of MacroGenics?

The Quality Investing for MacroGenics is 5/10.

What is the revenue of MacroGenics 2025?

The expected MacroGenics revenue is 71.43 M USD.

How high is the profit of MacroGenics 2025?

The expected MacroGenics profit is -127.36 M USD.

What is the business model of MacroGenics

MacroGenics Inc is a biopharmaceutical company that focuses on developing immunotherapy products for cancer and autoimmune diseases. The company aims to develop innovative therapies that can improve the lives of patients. The business model of MacroGenics comprises three main divisions: research, development, and commercialization. The company investigates the mechanisms behind the immune system to develop targeted products that can enhance immune control in diseases. To do this, the company utilizes its proprietary technology platform, the Dual-Affinity Re-Targeting (DART) technology. MacroGenics' research division focuses on the development of novel immunotherapies. An important focus is on the development of bispecific antibodies (BiTEs), which can specifically recognize and target two different antigens on tumor cells. The company already has several such products in the development phase, including MGD015, MGD017, and MGD019. MacroGenics' development division is involved in the manufacturing and testing of therapeutics and drugs that have emerged from the research division. The company has several products on the market, including the cancer immunotherapy Margetuximab (Margenza®) and Aes-103, a nasal spray for pain in cancer patients. The commercialization division of MacroGenics is responsible for the global marketing of the company's products. It also works closely with licensees and partners. One important partner of MacroGenics is Incyte Corporation, with whom the company collaborates on the development of cancer immunotherapies. MacroGenics also pursues a diversification strategy and expands into new therapy areas. The company recently entered into a partnership with Zai Lab Ltd. to jointly develop a novel antibody-drug conjugate (ADC) against HER2-positive cancer. The company has also initiated a program for the development of drugs for autoimmune diseases, including therapeutic antibodies. In addition to its commercial products, MacroGenics is also a leading provider of research services in the field of antibody and protein engineering and manufacturing. The company offers customized solutions for customers in the academic, pharmaceutical, and biotechnology sectors. Overall, MacroGenics' business model is aimed at advancing the development of innovative immunotherapy products and marketing them worldwide. With a broad product portfolio and an extensive research and development pipeline, the company is in a strong position to ensure the growth and success of the company in the future.

What is the MacroGenics dividend?

MacroGenics pays a dividend of 0 USD distributed over payouts per year.

How often does MacroGenics pay dividends?

The dividend cannot currently be calculated for MacroGenics or the company does not pay out a dividend.

What is the MacroGenics ISIN?

The ISIN of MacroGenics is US5560991094.

What is the MacroGenics WKN?

The WKN of MacroGenics is A1W6ND.

What is the MacroGenics ticker?

The ticker of MacroGenics is MGNX.

How much dividend does MacroGenics pay?

Over the past 12 months, MacroGenics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MacroGenics is expected to pay a dividend of 0 USD.

What is the dividend yield of MacroGenics?

The current dividend yield of MacroGenics is .

When does MacroGenics pay dividends?

MacroGenics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of MacroGenics?

MacroGenics paid dividends every year for the past 0 years.

What is the dividend of MacroGenics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is MacroGenics located?

MacroGenics is assigned to the 'Health' sector.

Wann musste ich die Aktien von MacroGenics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of MacroGenics from 10/8/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/8/2025.

When did MacroGenics pay the last dividend?

The last dividend was paid out on 10/8/2025.

What was the dividend of MacroGenics in the year 2024?

In the year 2024, MacroGenics distributed 0 USD as dividends.

In which currency does MacroGenics pay out the dividend?

The dividends of MacroGenics are distributed in USD.

All fundamentals about MacroGenics

Our stock analysis for MacroGenics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MacroGenics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.